Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Down 22.3% in December

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 18,800 shares, a decline of 22.3% from the November 30th total of 24,200 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily trading volume, of 933,500 shares, the days-to-cover ratio is presently 0.0 days.

Pasithea Therapeutics Price Performance

Shares of KTTA stock opened at $2.73 on Friday. Pasithea Therapeutics has a fifty-two week low of $2.37 and a fifty-two week high of $9.25. The stock’s 50-day simple moving average is $3.23 and its 200-day simple moving average is $4.35.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.